[1]
Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128: 40-50.
[2]
Zelnick LR, Weiss NS, Kestenbaum BR, et al. Diabetes and CKD in the United States population, 2009-2014. Clin J Am Soc Nephrol 2017; 12: 1984-90.
[3]
Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: A report from an ADA consensus conference. Diabetes Care 2014; 37: 2864-83.
[4]
de Zeeuw D. Microalbuminuria as an Early marker for cardiovascular disease. J Am Soc Nephrol 2006; 17: 2100-5.
[5]
Care D, Suppl SS. Microvascular complications and foot care: Standards of medical care in diabetes 2018. Diabetes Care 2018; 41: S105-18.
[6]
Levin A, Stevens PE, Bilous RW, et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150.
[7]
Anders H-J, Huber TB, Isermann B, et al. CKD in diabetes: Diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol 2018; 14: 361-77.
[8]
Fiorentino M, Bolignano D, Tesar V, et al. Renal biopsy in patients with diabetes: A pooled meta-analysis of 48 studies. Nephrol Dial Transplant 2017; 32: 97-110.
[9]
Zhuo L, Ren W, Li W, et al. Evaluation of renal biopsies in type 2 diabetic patients with kidney disease: A clinicopathological study of 216 cases. Int Urol Nephrol 2013; 45: 173-9.
[10]
Sharma SG, Bomback AS, Radhakrishnan J, et al. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol 2013; 8: 1718-24.
[11]
Suarez MLG, Thomas DB, Barisoni L, et al. Diabetic nephropathy: Is it time yet for routine kidney biopsy? World J Diabetes 2013; 4: 245.
[12]
Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas. Diabetologia 1999; 42: 263-85.
[13]
Gæde P, Tarnow L, Vedel P, et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004; 19: 2784-8.
[14]
Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type 2 diabetes. Diabetes 2006; 55: 1832-9.
[15]
Penno G, Solini A, Bonora E, et al. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens 2011; 29: 1802-9.
[16]
Pugliese G. Updating the natural history of diabetic nephropathy. Acta Diabetol 2014; 51: 905-15.
[17]
Lynch SK, Abràmoff MD. Diabetic retinopathy is a neurodegenerative disorder. Vision Res 2017; 139: 101-7.
[18]
Yau JWY, Rogers SL, Kawasaki R, et al. Global Prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35: 556-64.
[19]
Sabanayagam C, Banu R, Chee ML, et al. Incidence and progression of diabetic retinopathy: A systematic review. Lancet Diabetes Endocrinol 2018; 8587: 1-10.
[20]
Prospective UK, Study D. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
[21]
Turner R, Holman RR, Stratton IM, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 217: 703-13.
[22]
Keech A, Mitchell P, Summanen P, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 2007; 370: 1687-97.
[23]
ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-44.
[24]
Moss SE, Klein R, Kessler SD, et al. Comparison Between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy. Ophthalmology 1985; 92: 62-7.
[25]
Vujosevic S, Benetti E, Massignan F, et al. Screening for diabetic retinopathy: 1 and 3 nonmydriatic 45-degree digital fundus photographs vs. 7 standard early treatment diabetic retinopathy study fields. Am J Ophthalmol 2009; 148: 111-8.
[26]
Chin EK, Ventura B V, See K-Y, et al. Nonmydriatic fundus photography for teleophthalmology diabetic retinopathy screening in rural and urban clinics. Telemed e-Health 2014; 20: 102-8.
[27]
Wessel MM, Aaker GD, Parlitsis G, et al. Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. Retina 2012; 32: 785-91.
[28]
Goebel W, Kretzchmar-Gross T. Retinal thickness in diabetic retinopathy: A study using optical coherence tomography (OCT). Retina 2002; 22: 759-67.
[29]
Nesper PL, Soetikno BT, Zhang HF, et al. OCT angiography and visible-light OCT in diabetic retinopathy. Vision Res 2017; 139: 191-203.
[30]
Bolster NM, Giardini ME, Bastawrous A. The diabetic retinopathy screening workflow: Potential for smartphone imaging. J Diabetes Sci Technol 2016; 10: 318-24.
[31]
Russo A, Mapham W, Turano R, et al. Comparison of smartphone ophthalmoscopy with slit-lamp biomicroscopy for grading vertical cup-to-disc ratio. J Glaucoma 2016; 25: e777-81.
[32]
Bobb-Semple A, Ruvuma S, Onyango J, et al. Validity of smartphone fundus photography in diagnosing diabetic retinopathy at Mbarara Regional Referral Hospital, South Western. Uganda: J Opthalmol Eastern Central Southern Africa 2017; pp. 45-52.
[33]
Wilkinson CP, Ferris FL, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677-82.
[34]
Boulton AJM, Malik RA, Arezzo JC, et al. Diabetic somatic neuropathies. Diabetes Care 2004; 27: 1458-86.
[35]
Ang L, Jaiswal M, Martin C, et al. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep 2014; 14: 1-15.
[36]
Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: A position statement by the American diabetes association. Diabetes Care 2017; 40: 136-54.
[37]
Thomas P. Classification, differential diagnosis and staging of diabetic peripheral neuropathy. Diabetes 1997; 46: S54-7.
[38]
Dyck PJ, Albers JW, Andersen H, et al. Toronto expert panel on diabetic neuropathy. Diabetic polyneuropathies: Update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev 2011; 27: 620-8.
[39]
Albers JW, Pop-Busui R. Diabetic neuropathy: Mechanisms, emerging treatments and subtypes. Curr Neurol Neurosci Rep 2014; 14: 473.
[40]
Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity and treatments. Diabetes Care 2010; 33: 2285-93.
[41]
Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.
[42]
Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet 2010; 376: 419-30.
[43]
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-39.
[44]
Charles M, Ejskjaer N. Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: The ADDITION-Denmark study. Diabetes Care 2011; 34: 2244-9.
[45]
Singleton JR, Marcus RL, Jackson JE, et al. Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Transl Neurol 2014; 1: 844-9.
[46]
Petropoulos IN, Ponirakis G, Khan A, et al. Diagnosing diabetic neuropathy: Something old, something new. Diabetes Metab J 2018; 42: 255-69.
[47]
Freeman R. Not all neuropathy in diabetes is of diabetic etiology: Differential diagnosis of diabetic neuropathy. Curr Diab Rep 2009; 9: 423-31.
[48]
Gorson KC, Ropper AH. Additional causes for distal sensory polyneuropathy in diabetic patients. J Neurol Neurosurg Psychiatry 2006; 77: 354-8.
[49]
Callaghan BC, Kerber KA, Lisabeth LL, et al. Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy. JAMA Neurol 2014; 71: 1143-9.
[50]
Pop-Busui R, Evans GW, Gerstein HC, et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action To Control Cardiovascular Risk In Diabetes (ACCORD) trial. Diabetes Care 2010; 33: 1578-84.
[51]
Serhiyenko VA, Serhiyenko AA. Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World J Diabetes 2018; 9: 1-24.
[52]
NIH Consensus Development Panel on Impotence. Impotence - NIH Consensus Conference. JAMA 2013; 270: 83-90.
[53]
Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med 2009; 6: 1232-47.
[54]
Imprialos KP, Stavropoulos K, Doumas M, et al. Sexual dysfunction, cardiovascular risk and effects of pharmacotherapy. Curr Vasc Pharmacol 2018; 16: 130-42.
[55]
Lewis RW. Epidemiology of erectile dysfunction. Urol Clin North Am 2001; 28: 209-16.
[56]
Corona G, Giorda CB, Cucinotta D, et al. Sexual dysfunction at the onset of type 2 diabetes: The interplay of depression, hormonal and cardiovascular factors. J Sex Med 2014; 11: 2065-73.
[57]
Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, et al. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: A systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes 2013; 6: 99-109.
[58]
Ma RCW, So WY, Yang X, et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 2008; 51: 2045-50.
[59]
Chuang Y, Chung M, Wang P, et al. Albuminuria is an Independent risk factor of erectile dysfunction in men with type 2 diabetes. J Sex Med 2012; 9: 1055-64.
[60]
Chew SK, Taouk Y, Xie J, et al. Relationship between diabetic retinopathy, diabetic macular oedema and erectile dysfunction in type 2 diabetics. Clin Exp Ophthalmol 2013; 41: 683-9.
[61]
Cander S, Coban S, Altuner S, et al. Prevalence and correlates of erectile dysfunction in type 2 diabetes mellitus: A cross-sectional single-center study among Turkish patients. Metab Syndr Relat Disord 2014; 12: 324-9.
[62]
Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
[63]
Glina S, Sharlip ID, Hellstrom WJG. Modifying risk factors to prevent and treat erectile dysfunction. J Sex Med 2013; 10: 115-9.
[64]
Kalter-Leibovici O, Wainstein J, Ziv A, et al. Clinical, socioeconomic, and lifestyle parameters associated with erectile dysfunction among diabetic men. Diabetes Care 2005; 28: 1739-44.
[65]
Manolis A, Doumas M. Sexual dysfunction: The ‘prima ballerina’ of hypertension-related quality-of-life complications. J Hypertens 2008; 26: 2074-84.
[66]
Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: The HIM study. Int J Clin Pract 2006; 60: 762-9.
[67]
Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010; 57: 804-14.
[68]
Bachmann G, Avci D. Evaluation and management of female sexual dysfunction. endocrinologist 2004; 14: 337-45.
[69]
Pontiroli AE, Cortelazzi D, Morabito A. Female sexual dysfunction and diabetes: A systematic review and meta-analysis. J Sex Med 2013; 10: 1044-51.
[70]
Maseroli E, Scavello I, Vignozzi L. Cardiometabolic risk and female sexuality-part I. risk factors and potential pathophysiological underpinnings for female vasculogenic sexual dysfunction syndromes. Sex Med Rev 2018; 6(4): 508-24.
[71]
Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): Cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005; 31: 1-20.
342
36